Inventor · disambiguated record
David Marin Costa
Also filed as: MARIN COSTA DAVID
0 granted patents·17 pending applications·0 citations·filing 2020–2023
Files withUNIV TEXAS17
Top patents by PatentIndex Score
17 records- 0161US2025228942A1Methods for activation and expansion of engineered natural killer cells and combinations with antibodiesUNIV TEXAS·Filed 2023·Application pending·0 cites
- 0260US2024125765A1A method for selection of cryopreserved cord blood units for the manufacture of engineered natural killer cells with enhanced potency against cancerUNIV TEXAS·Filed 2022·Application pending·0 cites
- 0358US2024331837A1Selection of viral-specific cytotoxic t-cell lines for the management of viral infectionsUNIV TEXAS·Filed 2022·Application pending·0 cites
- 0455US2024382593A1Antibody loaded immune cells and methods for use in cancer treatmentUNIV TEXAS·Filed 2022·Application pending·0 cites
- 0554US2024252539A1Chimeric antigen receptor to target hla-g-positive cancersUNIV TEXAS·Filed 2022·Application pending·0 cites
- 0653US2024325444A1Chimeric antigen receptor to target trop-2-positive cancersUNIV TEXAS·Filed 2022·Application pending·0 cites
- 0753US2024189357A1Chimeric antigen receptors to target cd5-positive cancersUNIV TEXAS·Filed 2022·Application pending·0 cites
- 0852US2024165162A1Methods for activation and expansion of natural killer cells and combinations with bispecific antibodiesUNIV TEXAS·Filed 2022·Application pending·0 cites
- 0952US2023074303A1Cell immunotherapy for the treatment of cancerUNIV TEXAS·Filed 2021·Application pending·0 cites
- 1052US2025281612A1Cd27-extracellular domain car to target cd70-positive tumorsUNIV TEXAS·Filed 2022·Application pending·0 cites
- 1152US2024325443A1Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapyUNIV TEXAS·Filed 2022·Application pending·0 cites
- 1249US2022378739A1Natural killer cell immunotherapy for the treatment of glioblastoma and other cancersUNIV TEXAS·Filed 2020·Application pending·0 cites
- 1348US2022370500A1A method of engineering natural killer-cells to target bcma-positive tumorsUNIV TEXAS·Filed 2020·Application pending·0 cites
- 1448US2023210902A1Sars-cov-2-specific t cellsUNIV TEXAS·Filed 2021·Application pending·0 cites
- 1546US2022389383A1Large-scale combined car transduction and crispr gene editing of nk cellsUNIV TEXAS·Filed 2020·Application pending·0 cites
- 1646US2022403418A1Large-scale combined car transduction and crispr gene editing of b cellsUNIV TEXAS·Filed 2020·Application pending·0 cites
- 1745US2022288121A1Cell cryopreservation mediumUNIV TEXAS·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David Marin Costa files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →